Cargando…

The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer’s Disease, Parkinson’s Disease and Multiple Sclerosis

Brain small vessel disease (SVD) refers to a variety of structural and functional changes affecting small arteries and micro vessels, and manifesting as white matter changes, microbleeds and lacunar infarcts. Growing evidence indicates that SVD might play a significant role in the neurobiology of ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paolini Paoletti, Federico, Simoni, Simone, Parnetti, Lucilla, Gaetani, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125719/ https://www.ncbi.nlm.nih.gov/pubmed/34066951 http://dx.doi.org/10.3390/ijms22094958

Ejemplares similares

The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
por: Paolini Paoletti, Federico, et al.
Publicado: (2020)

Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers
por: Farotti, Lucia, et al.
Publicado: (2020)

Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation
por: Wojdała, Anna Lidia, et al.
Publicado: (2022)

CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment
por: Paolini Paoletti, Federico, et al.
Publicado: (2023)

A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
por: Bellomo, Giovanni, et al.
Publicado: (2020)

PEG-J replacement for duodenal levodopa infusion in Parkinson’s disease patients: a retrospective study
por: Simoni, Simone, et al.
Publicado: (2022)

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
por: Eusebi, Paolo, et al.
Publicado: (2018)

Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
por: Bellomo, Giovanni, et al.
Publicado: (2021)

Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease
por: Barba, Lorenzo, et al.
Publicado: (2022)

Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
por: Bellomo, Giovanni, et al.
Publicado: (2020)

Neuroinflammation and Alzheimer’s Disease: A Machine Learning Approach to CSF Proteomics
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis
por: Menculini, Giulia, et al.
Publicado: (2021)

Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington’s and Parkinson’s disease
por: Barschke, Peggy, et al.
Publicado: (2022)

Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers
por: Barba, Lorenzo, et al.
Publicado: (2022)

Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement Disorders
por: Tambasco, Nicola, et al.
Publicado: (2022)

Shared Mechanisms of Neurodegeneration in Alzheimer's Disease and Parkinson's Disease
por: Xie, Anmu, et al.
Publicado: (2014)

Synaptic Dysfunction in Multiple Sclerosis: A Red Thread from Inflammation to Network Disconnection
por: Bellingacci, Laura, et al.
Publicado: (2021)

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
por: Sjödin, Simon, et al.
Publicado: (2019)

Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease
por: Paciotti, Silvia, et al.
Publicado: (2020)

Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers
por: Gaetani, Lorenzo, et al.
Publicado: (2020)

Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer’s disease continuum
por: Paciotti, Silvia, et al.
Publicado: (2023)

Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease
por: Lawn, Timothy, et al.
Publicado: (2021)

Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals
por: Chipi, Elena, et al.
Publicado: (2019)

Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease?
por: Parnetti, Lucilla, et al.
Publicado: (2010)

Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Issue of Diurnal Variation
por: Cicognola, Claudia, et al.
Publicado: (2015)

Advances in the Pathogenesis of Alzheimer’s Disease: Focusing on Tau-Mediated Neurodegeneration
por: Duan, Yale, et al.
Publicado: (2012)

The Role of Microglia in Retinal Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma
por: Ramirez, Ana I., et al.
Publicado: (2017)

Neurodegeneration and convergent factors contributing to the deterioration of the cytoskeleton in Alzheimer's disease, cerebral ischemia and multiple sclerosis (Review)
por: Gutiérrez-Vargas, Johanna Andrea, et al.
Publicado: (2022)

Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
por: Wardlaw, Joanna M, et al.
Publicado: (2013)

From cradle to grave: neurogenesis, neuroregeneration and neurodegeneration in Alzheimer’s and Parkinson’s diseases
por: Wakhloo, Debia, et al.
Publicado: (2022)

Neurodegeneration and neuroprotection in Parkinson's disease /
Publicado: (1996)

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia
por: Chiasserini, Davide, et al.
Publicado: (2017)

Kynurenines, neurodegeneration and Alzheimer’s disease
por: Kincses, Zsigmond Tamas, et al.
Publicado: (2010)

Mapping pathogenic processes contributing to neurodegeneration in Drosophila models of Alzheimer's disease
por: Bergkvist, Liza, et al.
Publicado: (2020)

Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis
por: Parnetti, Lucilla, et al.
Publicado: (2019)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016)

Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases
por: Jagaran, Keelan, et al.
Publicado: (2021)

Cyclooxygenase and Neuroinflammation in Parkinson’s Disease Neurodegeneration
por: Bartels, Anna L, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_57kmokbho7fqgdr6bv08stm817